Tags · Sourcing
research use only
Material not approved for human use, sold for laboratory research.
Related in this group: certificate of analysis · batch & lot numbers · Janoshik Analytical · Medutest · PeptideMeter · VendorInvestigate · third-party testing · blind sampling · documentation quality · underdosing · mislabelling · customs
56 topics · page 1 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Compounds this community declines to help with, and why — does this still hold?
Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…
|
+3 | 7 | 26k | 7h |
|
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…
|
+8 | 12 | 15k | 17h |
|
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…
|
+7 | 11 | 31k | 19h |
|
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
|
+72 | 81 | 44k | 1d |
|
Follow-up: How compounding permissions changed when supply normalised
How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion, following the…
|
+72 | 77 | 1.5k | 1d |
|
Why chargeback is not the safety net people assume
Asking directly, because I could not find a straight answer: Why chargeback is not the safety net people assume A logistics question, since the answers here are usually better than anywhere else I have…
|
+22 | 26 | 2.5k | 2d |
|
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
2 | 38k | 2d | |
|
Coming back to: Payment method and the leverage it gives you, ranked
Payment method and the leverage it gives you, ranked — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked…
|
+21 | 26 | 43k | 2d |
|
[2026 update] Currency conversion and the cost you did not see
Posting this under the heading it deserves: Currency conversion and the cost you did not see Everything below is what sits behind that. A logistics question, since the answers here are usually better than…
|
+21 | 26 | 52k | 2d |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+87 | 94 | 1.1k | 21d |
|
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…
|
+21 | 25 | 4.9k | 22d |
|
Documenting a payment dispute without naming and shaming — the long version
Posting this under the heading it deserves: Documenting a payment dispute without naming and shaming — the long version Everything below is what sits behind that. I would like to talk about documentation…
|
2 | 32k | 1mo | |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
2 | 1.8k | 2mo | |
|
Documenting a payment dispute without naming and shaming
Documenting a payment dispute without naming and shaming — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from…
|
+5 | 9 | 9.8k | 2mo |
|
Currency conversion and the cost you did not see
Currency conversion and the cost you did not see — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked for.…
|
2 | 44k | 2mo | |
|
Second pass at: Why chargeback is not the safety net people assume
Second pass at: Why chargeback is not the safety net people assume Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are usually…
|
2 | 25k | 3mo | |
|
Why this community will not facilitate a group purchase
Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase A logistics question, since the answers here are usually better than anywhere else I have…
|
2 | 40k | 3mo | |
|
A payment that went through twice: how it was resolved
A payment that went through twice: how it was resolved Writing it up because I had to work it out twice and would rather nobody else did. I would like to talk about documentation quality as a signal,…
|
+20 | 24 | 55k | 3mo |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…
|
+72 | 78 | 23k | 3mo |
|
About the Regulatory category
Research-use-only status, compounding rules, import restrictions, and the primary documents behind them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 49k | 4mo | |
|
Labelling requirements for research chemicals
Labelling requirements for research chemicals — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked for.…
|
+5 | 9 | 45k | 4mo |
|
Second pass at: What to keep a record of at the point of payment
Second pass at: What to keep a record of at the point of payment — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…
|
+14 | 18 | 1.9k | 4mo |
|
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
+100 | 110 | 37k | 5mo |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
|
+35 | 39 | 688 | 5mo |
|
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
|
+40 | 44 | 2.8k | 6mo |
|
Coming back to: Payment mechanics and the recovery options that do not exist
On the subject in the title: Payment mechanics and the recovery options that do not exist Working notes rather than a conclusion. Structured report rather than an opinion, following the format the maintainers…
|
+7 | 11 | 2.6k | 7mo |
|
Prescription requirements and telehealth models
Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are usually better than anywhere…
|
+91 | 97 | 5.4k | 7mo |
|
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…
|
+22 | 26 | 53k | 7mo |
|
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+8 | 12 | 51k | 7mo |
|
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. A logistics question, since the…
|
+50 | 56 | 780 | 8mo |